1092 related articles for article (PubMed ID: 32603972)
81. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
[TBL] [Abstract][Full Text] [Related]
82. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
83. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
[TBL] [Abstract][Full Text] [Related]
84. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
[TBL] [Abstract][Full Text] [Related]
85. Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status.
Li TR; Lyu DY; Liu FQ;
J Alzheimers Dis; 2022; 90(3):1123-1138. PubMed ID: 36213998
[TBL] [Abstract][Full Text] [Related]
86. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
Hohman TJ; Bell SP; Jefferson AL;
JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
[TBL] [Abstract][Full Text] [Related]
87. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
88. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
89. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
[TBL] [Abstract][Full Text] [Related]
90. Prevalence of Alzheimer's pathologic endophenotypes in asymptomatic and mildly impaired first-degree relatives.
Lampert EJ; Roy Choudhury K; Hostage CA; Petrella JR; Doraiswamy PM;
PLoS One; 2013; 8(4):e60747. PubMed ID: 23613741
[TBL] [Abstract][Full Text] [Related]
91. The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey.
Caprioglio C; Garibotto V; Jessen F; Frölich L; Allali G; Assal F; Frisoni GB; Altomare D;
J Alzheimers Dis; 2022; 89(2):535-551. PubMed ID: 35912743
[TBL] [Abstract][Full Text] [Related]
92. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.
van Waalwijk van Doorn LJ; Gispert JD; Kuiperij HB; Claassen JA; Arighi A; Baldeiras I; Blennow K; Bozzali M; Castelo-Branco M; Cavedo E; Emek-Savaş DD; Eren E; Eusebi P; Farotti L; Fenoglio C; Ormaechea JF; Freund-Levi Y; Frisoni GB; Galimberti D; Genc S; Greco V; Hampel H; Herukka SK; Liu Y; Lladó A; Lleó A; Nobili FM; Oguz KK; Parnetti L; Pereira J; Picco A; Pikkarainen M; de Oliveira CR; Saka E; Salvadori N; Sanchez-Valle R; Santana I; Scarpini E; Scheltens P; Soininen H; Tarducci R; Teunissen C; Tsolaki M; Urbani A; Vilaplana E; Visser PJ; Wallin AK; Yener G; Molinuevo JL; Meulenbroek O; Verbeek MM
J Alzheimers Dis; 2017; 56(2):543-555. PubMed ID: 28059783
[TBL] [Abstract][Full Text] [Related]
93. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.
Landau SM; Horng A; Fero A; Jagust WJ;
Neurology; 2016 Apr; 86(15):1377-1385. PubMed ID: 26968515
[TBL] [Abstract][Full Text] [Related]
94. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI).
Nathan PJ; Lim YY; Abbott R; Galluzzi S; Marizzoni M; Babiloni C; Albani D; Bartres-Faz D; Didic M; Farotti L; Parnetti L; Salvadori N; Müller BW; Forloni G; Girtler N; Hensch T; Jovicich J; Leeuwis A; Marra C; Molinuevo JL; Nobili F; Pariente J; Payoux P; Ranjeva JP; Rolandi E; Rossini PM; Schönknecht P; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
Neurobiol Aging; 2017 May; 53():1-10. PubMed ID: 28189924
[TBL] [Abstract][Full Text] [Related]
95. Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds.
Duits FH; Hernandez-Guillamon M; Montaner J; Goos JD; Montañola A; Wattjes MP; Barkhof F; Scheltens P; Teunissen CE; van der Flier WM
J Alzheimers Dis; 2015; 48(3):711-20. PubMed ID: 26402072
[TBL] [Abstract][Full Text] [Related]
96. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
97. Predicting conversion of patients with Mild Cognitive Impairment to Alzheimer's disease using bedside cognitive assessments.
Clarke A; Ashe C; Jenkinson J; Rowe O; A D N I ; Hyland P; Commins S
J Clin Exp Neuropsychol; 2022 Dec; 44(10):703-712. PubMed ID: 36803664
[TBL] [Abstract][Full Text] [Related]
98. Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias.
Cicognola C; Hansson O; Scheltens P; Kvartsberg H; Zetterberg H; Teunissen CE; Blennow K
Alzheimers Res Ther; 2021 Feb; 13(1):38. PubMed ID: 33557920
[TBL] [Abstract][Full Text] [Related]
99. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
[TBL] [Abstract][Full Text] [Related]
100. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
